Delving into the Latest Updates on NS 1231 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Brain Ischemia

Inactive Indication-

Originator Organization

Neurosearch

Active Organization

Neurosearch

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractNS 1231 [5‐(4‐chlorophenyl)‐6,7,8,9‐tetrahydro‐1H‐pyrrolo‐[3.2‐h]naphthalene‐2,3‐dione‐3‐oxime] belongs to a chemical series of compounds, which exhibit neurotrophic‐like activities. In vitro, NS 1231 rescued nerve growth factor (NGF)‐ differentiated PC12 cells from death induced by withdrawal of trophic factors. In addition, NS 1231 stimulated NGF‐induced neurite outgrowth of undifferentiated PC12 cells. At the molecular level, NS 1231 enhanced NGF‐induced signalling events, such as TrkA phosphorylation at the Shc‐binding site Tyr490 as well as ERK activation in PC12 cells. Moreover, NS 1231 reduced NMDA‐induced excitotoxicity in organotypic hippocampal slice cultures. In a gerbil model of transient global ischaemia, treatment with NS 1231 reduced the delayed loss of neurons in the hippocampal CA1 layer. Furthermore, NS 1231 treatment resulted in a 43% reduction in total infarct volume in the mouse middle cerebral artery occlusion (MCAO) model. The present data thus implicate a therapeutic potential of NS 1231 or structural analogues in treatment of cerebral ischaemia.

100 Deals associated with NS 1231

Login to view more data